3N Bio Revenue

About 3N Bio

We are a life science-start-up that set out as a spin-off from SciLifeLab/Karolinska Institutet. Based on our work on microbial metadegradomics we aim to increase efficiency, safety and speed in the development of small molecules modulating the microbiome. Our technology provides immediate information of the effect of new drug substances on the microbiome. Currently, our team focus on the application of this technology to measure cellular growth at the molecular level and to speed up the diagnosis of phenotypic antimicrobial resistance . OUR MISSION The rapid emergence of antibiotic-resistant bacteria and multidrug-resistant pathogenic fungi pose a threat to global health. If no urgent actions are taken, by 2050, antimicrobial resistance (AMR) will cause an estimated loss of 10 million lives and $US100 trillion. Fast and accurate diagnosis of antimicrobial resistant strains is key to contain the rise of AMR, limit its spread and provide adequate treatment to patients. At 3N Bio we work on the development quick and simple tests able to detect antimicrobial resistance independent of the drug resistance mechanism used. We aim to provide fast diagnosis for bacterial infections and provide actionable recommendation for antibiotic usage. Our final goal is to accelerate diagnosis, improve patient survival, and contribute to individualized and rational use of antibiotics.

View contact profiles from 3N Bio